Recombinant Rhesus macaque FLT1 protein, Mouse IgG2a Fc-tagged, low endotoxin

• Cat.No.: FLT1-379R
• Product Overview: Recombinant Rhesus macaque FLT1 protein (Ser27-Asn756)(low endotoxin), fused to Mouse IgG2a Fc tag at C-terminus, was expressed in human 293 cells (HEK293).

Specification

• Description: Vascular endothelial growth factor receptor 1 (VEGFR1) is also known as Fms-like tyrosine kinase 1 (FLT-1), Tyrosine-protein kinase receptor FLT, is a single-pass type I membrane protein and secreted protein which belongs to the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily. VEGFR1 is detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues and specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. VEGFR1 acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR1 may play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. VEGFR1 can promote endothelial cell proliferation, survival and angiogenesis in adulthood.
• Source: HEK293
• Species: Rhesus macaque
• Tag: mIgG2a
• Form: Lyophilized from 0.22 um filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose.
• Molecular Mass: The protein has a calculated MW of 109.1 kDa. The protein migrates as 130 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
• Protein length: 730
• Endotoxin: Less than 0.1 EU per ug by the LAL method.
• Purity: >95% as determined by SDS-PAGE.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: FLT1
• Official Symbol: FLT1
• Synonyms: FLT, FLT-1, VEGFR-1, VEGFR1
• Gene ID: 574133
• mRNA Refseq: XM_001117928.4
• Protein Refseq: XP_001117928.3
• UniProt ID: F7FAY2

Reviews

07/08/2019

the FLT1 protein is an excellent choice for researchers due to its high quality, reliability, and the comprehensive technical support provided by the manufacturer.

07/17/2018

The manufacturer of FLT1 protein provides excellent technical support, ensuring that researchers receive prompt assistance and guidance when encountering any challenges or difficulties.

05/27/2016

Researchers can confidently incorporate FLT1 protein into their experiments, knowing that they have access to a reliable resource that will meet their experimental needs effectively.

Q&As

How is FLT1 linked to preeclampsia in pregnancy?

Elevated levels of soluble FLT1 have been associated with preeclampsia, a pregnancy complication. Soluble FLT1 acts as a decoy receptor, reducing the bioavailability of VEGF and contributing to vascular dysfunction.

How does FLT1 contribute to retinal diseases such as diabetic retinopathy?

FLT1 has been implicated in retinal diseases like diabetic retinopathy, where abnormal blood vessel growth can lead to vision impairment. Inhibiting FLT1 may help regulate angiogenesis in such conditions.

How is FLT1 expression regulated in the human body?

FLT1 expression is regulated by various factors, including VEGF itself, as well as hypoxia and inflammation. These factors influence the balance of angiogenic signaling.

Can FLT1 be a biomarker for certain diseases?

Yes, elevated levels of soluble FLT1 have been investigated as potential biomarkers for conditions like preeclampsia, cancer, and certain cardiovascular diseases.

Can FLT1 be targeted for anti-angiogenic therapy?

Yes, targeting FLT1 is a strategy for anti-angiogenic therapy. Inhibiting FLT1 can impede blood vessel formation, limiting the blood supply to tumors and potentially slowing their growth.